GlassScriptPhysician profile
Daniel Camilo Rodriguez
NPI 1184913980
$2,432.48
in general payments reported to CMS, 2019-2025
13 companies · $112 in 2025
The $112 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,438 · 2020: $581 · 2021: $78.93 · 2022: $143 · 2023: $33.51 · 2024: $45.53 · 2025: $112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $190.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,244.71 | 2019-2024 | Supera, Emboshield Nav6 |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $419.32 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $273.37 | 2019-2023 | Andexxa |
| Lilly USA, LLC | $111.91 | 2025 | Zepbound |
| Janssen Pharmaceuticals, INC | $84.82 | 2022-2023 | Xarelto |
| Ge Healthcare | $71.38 | 2019-2021 | |
| Alk-Abello, INC | $60.50 | 2022 | |
| Boston Scientific Corporation | $59.09 | 2019 | |
| Lantheus Medical Imaging, INC. | $34.12 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.78 | 2020 | |
| Amgen INC. | $15.41 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $13.32 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $12.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Rodriguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.